Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

Feltkamp, Mariet C.W.; Smits, Henk L.; Vierboom, Michel; Minnaar, R. P.; Jongh, B. M. De; Drijfhout, Jan W.; Schegget, Jan ter; Melief, Cornelis J.M.; Kast, W. Martin

doi:10.1002/eji.1830230929

Cited by 725 publications

(552 citation statements)

References 39 publications

Supporting

Mentioning

520

Contrasting

Unclassified

Order By: Relevance

“…To determine the frequency of antigen-specific CD8 + T cell precursors, splenocytes isolated from vaccinated mice were stimulated with an E7-specific CTL epitope (aa 49-57 of E7 protein). 23 Our results indicated that E7-specific T cells could be detected in mice using different routes of DC-E7 vaccination. Intramuscular immunization with DC-E7 induced the highest number of E7-specific CTL precursors ( Figure 7).…”

Section: Dc-e7 Vaccine Administered Via the Intramuscular Route Of Admentioning

confidence: 57%

Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity

Wang¹,

Ling²,

Im³

et al. 2000

Gene Ther

110

View full text Add to dashboard Cite

Dendritic cells (DCs) are highly efficient antigen-presenting cells capable of priming both cytotoxic and helper T cells in vivo. Recent studies have demonstrated the potential use of DCs that are modified to carry tumor-specific antigens in cancer vaccines. However, the optimal administration route of DC-based vaccines to generate the greatest anti-tumor effect remains to be determined. This study is aimed at comparing the levels of immune responses and anti-tumor effect generated through different administration routes of DCbased vaccination. We chose the E7 gene product of human papillomavirus (HPV) as the model antigen and generated a stable DC line (designated as DC-E7) that constitutively

show abstract

Section: Dc-e7 Vaccine Administered Via the Intramuscular Route Of Admentioning

confidence: 57%

Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity

Wang¹,

Ling²,

Im³

et al. 2000

Gene Ther

110

View full text Add to dashboard Cite

show abstract

“…Splenocytes were harvested 1 week after the last vaccination. Before intracellular cytokine staining, 5 × 10 6 pooled splenocytes from each vaccination group were incubated for 16 h with either 1 μg/ml of E7 peptide (aa 49-57) containing an MHC class I epitope [29] for detecting E7-specific CD8 + T cell precursors or 10 μg/ml of E7 peptide (aa 30-67) containing an MHC class II epitope [30] for detecting E7-specific CD4 + T cell precursors. Cell surface marker staining for CD8 or CD4 and intracellular cytokine staining for IFN-γ, as well as flow cytometry analysis, were performed using conditions described previously [31].…”

Section: Intracellular Cytokine Staining and Flow Cytometry Analysismentioning

confidence: 99%

Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis

Cheng

Hung

Chen

et al. 2005

Vaccine

View full text Add to dashboard Cite

Antigen-specific cancer immunotherapy and antiangiogenesis are feasible strategies for cancer therapy because they can potentially treat systemic tumors at multiple sites in the body while discriminating between neoplastic and non-neoplastic cells. We have previously developed a DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus-16 E7 and have found that this vaccine generates strong E7-specific antitumor immunity and antiangiogenic effects in vaccinated mice. In this study, we characterized the domains of CRT to produce E7-specific antitumor immunity and antiangiogenic effects by generating DNA vaccines encoding each of the three domains of CRT (N, P, and C domains) linked to the HPV-16 E7 antigen. We found that C57BL/6 mice vaccinated intradermally with DNA encoding the N domain of CRT (NCRT), the P domain of CRT (PCRT), or the C domain of CRT (CCRT) linked with E7 exhibited significant increases in E7-specific CD8 + T cell precursors and impressive antitumor effects against E7-expressing tumors compared to mice vaccinated with wild-type E7 DNA. In addition, the N domain of CRT also showed antiangiogenic properties that might have contributed to the antitumor effect of NCRT/E7. Thus, the N domain of CRT can be linked to a tumor antigen in a DNA vaccine to generate both antigen-specific immunity and antiangiogenic effects for cancer therapy.

show abstract

“…48 In a Phase I/II clinical trial, 19 terminally ill cervical cancer patients were immunized with HLA-A*0201-restricted HPV-16 E7 peptide, with confirmed tolerability but no detectable CTL response. 49 Another Phase II clinical trial in patients with end-stage cervical cancer used E6 or E7 HLA-A*0201-binding peptides pulsed onto cytokine-stimulated autologous peripheral blood mononuclear cells.…”

Section: Peptide and Protein-based Vaccinesmentioning

confidence: 99%

Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer

Eskander

Tewari

2015

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: In 2014, the US Food and Drug Administration approved the first targeted agent, bevacizumab, in the treatment of advanced stage, persistent, or recurrent cervical cancer. This oncologic milestone has catalyzed interest in the investigation of alternate therapies, including immunotherapy, in an effort to extend life and possibly cure patients with advanced stage disease.Methods: This review article focuses on the evolving paradigm of immunotherapy in the treatment of cervical cancer, describing the biologic basis of this treatment modality and discussing applicable Phase I to II clinical trials.Findings: To date several trials have been conducted exploring vaccine-based therapies, adoptive T-cell therapy, and immune-modulating agents in patients with cervical cancer with promising results.Implications: Immunotherapy represents a promising therapeutic paradigm in the treatment of advanced cervical cancer. Additional investigation is warranted to try and identify alternate immune targets and predictors of response, allowing for the selection of patients most likely to benefit from immune-based treatments. (Clin Ther. 2015;37:20-38) & 2015 Elsevier HS Journals, Inc. All rights reserved.

show abstract

Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells

Cited by 725 publications

References 39 publications

Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity

Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity

Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis

Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer

Contact Info

Product

Resources

About